**Table 5.** Studies on PUFAs and metabolic axis.

### **5. Summary and Future Perspectives**

In conclusion, there seems to be evidence that ω-3 PUFA consumption may be clinically beneficial in the treatment and clinical management of MOSH patients.

The ability of ω-3 PUFAs to act on some pathological aspects of MOSH, such as obesity, inflammation, metabolic and cardiovascular disorders, coupled with their optimal safety profile, leads us to the postulation that ω-3 PUFA assumption could be a valuable tool in ameliorating the clinical manifestations of MOSH syndrome.

In pursuance to assess this conclusion in a definitive manner and in order to define the most advantageous dosage, randomized clinical trials on a large population sample are required. Moreover, it would be interesting and useful to conduct experimental studies exploring the possible effects of ω-3 PUFA consumption on hormone profile, on the sexual sphere (T concentrations) and on body composition.

**Author Contributions:** Conceptualization, A.N. and N.D.D.; writing—original draft preparation, A.N., G.M., F.D.D., M.D.L., A.P.Z. and G.W.J.; writing—review and editing, N.D.D. and A.D.L.; supervision, N.D.D. and A.N. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

### **Abbreviation List**



### **References**


© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
